株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃癌:パイプライン製品の分析

Gastric Cancer - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232773
出版日 ページ情報 英文 1283 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.15円で換算しております。
Back to Top
胃癌:パイプライン製品の分析 Gastric Cancer - Pipeline Review, H1 2018
出版日: 2018年04月30日 ページ情報: 英文 1283 Pages
概要

胃癌は、胃の内膜に発生する悪性腫瘍で、その兆候と症状には、倦怠感、腹痛、嘔吐、体重の減少、食後の膨満感、胸やけ、消化不良などがあります。胃癌を罹患する原因としては、喫煙、2悪性貧血、胃のポリープ、ピロリ菌への感染、胃癌を発症しやすい家系などが挙げられます。

当レポートでは、胃癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

胃癌 - 概要

胃癌 - 治療薬の開発

胃癌 - 治療薬の評価

胃癌の治療薬開発に従事している企業

薬剤プロファイル

胃癌 - 休止中のプロジェクト

胃癌 - 開発が中止された製品

胃癌 - 製品開発のマイルストーン

付録

目次
Product Code: GMDHC10355IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Gastric Cancer - Overview
  • Gastric Cancer - Therapeutics Development
  • Gastric Cancer - Therapeutics Assessment
  • Gastric Cancer - Companies Involved in Therapeutics Development
  • Gastric Cancer - Drug Profiles
  • Gastric Cancer - Dormant Projects
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Gastric Cancer, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 13: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 14: Products under Development by Companies, H1 2018
  • Table 15: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 16: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Table 17: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Table 18: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Table 19: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Table 20: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Table 21: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Table 22: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Table 23: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Table 24: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Table 25: Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Table 26: Products under Development by Companies, H1 2018 (Contd..12), H1 2018
  • Table 27: Products under Development by Companies, H1 2018 (Contd..13), H1 2018
  • Table 28: Products under Development by Companies, H1 2018 (Contd..14), H1 2018
  • Table 29: Products under Development by Companies, H1 2018 (Contd..15), H1 2018
  • Table 30: Products under Development by Companies, H1 2018 (Contd..16), H1 2018
  • Table 31: Products under Development by Companies, H1 2018 (Contd..17), H1 2018
  • Table 32: Products under Development by Companies, H1 2018 (Contd..18), H1 2018
  • Table 33: Products under Development by Universities/Institutes, H1 2018
  • Table 34: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Table 35: Number of Products by Stage and Target, H1 2018
  • Table 36: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 37: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Table 38: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Table 39: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
  • Table 40: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
  • Table 41: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
  • Table 42: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 43: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 44: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Table 45: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Table 46: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
  • Table 47: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
  • Table 48: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
  • Table 49: Number of Products by Stage and Route of Administration, H1 2018
  • Table 50: Number of Products by Stage and Molecule Type, H1 2018
  • Table 51: Gastric Cancer - Pipeline by 3SBio Inc, H1 2018
  • Table 52: Gastric Cancer - Pipeline by AbbVie Inc, H1 2018
  • Table 53: Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2018
  • Table 54: Gastric Cancer - Pipeline by Abion Inc, H1 2018
  • Table 55: Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Table 56: Gastric Cancer - Pipeline by ADC Therapeutics SA, H1 2018
  • Table 57: Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Table 58: Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Table 59: Gastric Cancer - Pipeline by Alteogen Inc, H1 2018
  • Table 60: Gastric Cancer - Pipeline by Ambrx Inc, H1 2018
  • Table 61: Gastric Cancer - Pipeline by amcure GmbH, H1 2018
  • Table 62: Gastric Cancer - Pipeline by Amgen Inc, H1 2018
  • Table 63: Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2018
  • Table 64: Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018
  • Table 65: Gastric Cancer - Pipeline by arGEN-X BV, H1 2018
  • Table 66: Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Table 67: Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Table 68: Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
  • Table 69: Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Table 70: Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Table 71: Gastric Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
  • Table 72: Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Table 73: Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2018
  • Table 74: Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Gastric Cancer, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
  • Figure 4: Number of Products by Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top